ANX-042

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C189H312N58O53S4
Molecular Weight	4373.116
Optical Activity	UNSPECIFIED
Defined Stereocenters	38 / 38
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CC(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CC7=CNC=N7)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H]8CSSC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]9CCCN9C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CC%10=CC=CC=C%10)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N8)C(=O)N%11CCC[C@H]%11C(=O)N[C@@H](C(C)C)C(O)=O

InChI

InChIKey=IRRLKLXYIZBPPF-YTGPIHSWSA-N

InChI=1S/C189H312N58O53S4/c1-15-103(11)149-177(290)234-127(94-253)167(280)233-126(93-252)166(279)232-125(92-251)165(278)231-124(91-250)156(269)211-85-142(258)215-118(77-99(3)4)153(266)208-87-144(260)217-129(168(281)219-108(41-20-24-60-190)151(264)206-83-140(256)213-109(42-21-25-61-191)158(271)229-122(80-106-82-202-98-212-106)181(294)241-68-32-49-132(241)172(285)230-121(78-100(5)6)180(293)247-74-38-55-138(247)184(297)243-70-34-50-133(243)171(284)226-117(47-30-66-205-189(200)201)179(292)246-73-37-54-137(246)183(296)244-71-35-51-134(244)173(286)235-128(95-254)182(295)242-69-33-52-135(242)175(288)239-150(104(12)16-2)185(298)245-72-36-53-136(245)174(287)237-148(102(9)10)186(299)300)96-303-304-97-130(218-145(261)88-210-155(268)123(90-249)216-143(259)86-207-152(265)114(56-57-139(195)255)225-176(289)147(101(7)8)236-163(276)116(59-76-302-14)223-160(273)112(44-23-27-63-193)224-170(283)131-48-31-67-240(131)178(291)107(194)89-248)169(282)227-119(79-105-39-18-17-19-40-105)154(267)209-84-141(257)214-110(45-28-64-203-187(196)197)157(270)220-111(43-22-26-62-192)159(272)222-115(58-75-301-13)161(274)228-120(81-146(262)263)164(277)221-113(162(275)238-149)46-29-65-204-188(198)199/h17-19,39-40,82,98-104,107-138,147-150,248-254H,15-16,20-38,41-81,83-97,190-194H2,1-14H3,(H2,195,255)(H,202,212)(H,206,264)(H,207,265)(H,208,266)(H,209,267)(H,210,268)(H,211,269)(H,213,256)(H,214,257)(H,215,258)(H,216,259)(H,217,260)(H,218,261)(H,219,281)(H,220,270)(H,221,277)(H,222,272)(H,223,273)(H,224,283)(H,225,289)(H,226,284)(H,227,282)(H,228,274)(H,229,271)(H,230,285)(H,231,278)(H,232,279)(H,233,280)(H,234,290)(H,235,286)(H,236,276)(H,237,287)(H,238,275)(H,239,288)(H,262,263)(H,299,300)(H4,196,197,203)(H4,198,199,204)(H4,200,201,205)/t103-,104-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,147-,148-,149-,150-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C189H312N58O53S4
Molecular Weight	4373.116
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	38 / 38
E/Z Centers	17
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 15:42:15 GMT 2023` Edited by `admin` on `Sat Dec 16 15:42:15 GMT 2023`
Record UNII	ZV0MCR055T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANX-042

Common Name

English

ASBNP.1

Common Name

English

L-VALINE, L-SERYL-L-PROLYL-L-LYSYL-L-METHIONYL-L-VALYL-L-GLUTAMINYLGLYCYL-L-SERYLGLYCYL-L-CYSTEINYL-L-PHENYLALANYLGLYCYL-L-ARGINYL-L-LYSYL-L-METHIONYL-L-.ALPHA.-ASPARTYL-L-ARGINYL-L-ISOLEUCYL-L-SERYL-L-SERYL-L-SERYL-L-SERYLGLYCYL-L-LEUCYLGLYCYL-L-CYSTEIN

Systematic Name

English

BNP.1

Common Name

English

ANX 042

Code

English

Code System Code Type Description

PUBCHEM

145722011

Created by admin on Sat Dec 16 15:42:15 GMT 2023 , Edited by admin on Sat Dec 16 15:42:15 GMT 2023

PRIMARY

CAS

1434212-55-1

Created by admin on Sat Dec 16 15:42:15 GMT 2023 , Edited by admin on Sat Dec 16 15:42:15 GMT 2023

PRIMARY

FDA UNII

ZV0MCR055T

Created by admin on Sat Dec 16 15:42:15 GMT 2023 , Edited by admin on Sat Dec 16 15:42:15 GMT 2023

PRIMARY

Related Record Type Details


					ZV0MCR055T

ANX-042

ACTIVE MOIETY

Comments:

Results: Under Na replete conditions, ANX-042 was tolerated up to 0.03 .MU.g/kg/min, with 3 of 4 subjects requiring discontinuation of ANX-042 infusion of 0.065 .MU.g/kg/min due to persistent symptomatic orthostatic hypotension. The effects on cGMP activation at end of infusion are shown Table 1. There were no consistent changes in urinary parameters or neurohormones in these healthy volunteers.


					ZV0MCR055T

ANX-042

ACTIVE MOIETY

Comments:

Drug: ANX 042(Primary); Indications: Acute heart failure, Chronic heart failure, Decompensated heart failure; Focus: Adverse reaction; Sponsor: Anexon; Most Recent Events: 18 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association., 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov., 05 Nov 2012 Planned number of patients changed from 18 to 30 as reported by ClinicalTrials.gov.


					ZV0MCR055T

ANX-042

ACTIVE MOIETY

Comments:

Originator: Mayo Clinic; Developer: Anexon; Class: Heart failure therapy, Natriuretic peptide Mechanism of Action: Undefined mechanism; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: No development reported for Heart failure, Kidney disorders; Most Recent Events: 19 Apr 2016 No recent reports on development identified - Phase-I for Kidney disorders (In volunteers) in USA (IV), 19 Apr 2016 No recent reports on development identified - Phase-I for Heart failure (In volunteers) in USA (IV), 07 Aug 2012 Phase-I clinical trials in Heart failure in USA (IV)